

Barcelona, Spain,
December 17th, 2019

AlmirallShare is responsible for 50% of the private-public collaborations of Almirall

- **Almirall has just started four new collaborations with the Dublin City University, IDIBAPS in Barcelona, the University of Turin and the Université de Namur.**
- **Since its launch in 2017, over 850 scientists have subscribed to the platform and have submitted nearly 350 proposals. So far, Almirall is currently working on 6 research collaborations.**

AlmirallShare, the open innovation platform of **Almirall, S.A. (ALM)**, is responsible for around 50% of the private-public collaborations driven by Almirall. Since its launch in 2017, more than 850 scientists have shown interest in participating and nearly 350 proposals have been received. Currently, there are six projects ongoing including new collaborations with the School of Biotechnology of Dublin City University, the Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), EvoBiotech (spin-off from the University of Turin) and the Université de Namur. Additionally, three new collaborative projects are expected to start very soon.

The main objective of **AlmirallShare** is to facilitate the establishment of collaborations in dermatological research and find innovative solutions for skin health. By putting together the science and creativity of experts around the world and Almirall's own expertise, **AlmirallShare** accelerates the generation of new treatments for skin conditions.

"We are very pleased with the results that AlmirallShare has achieved so far. We created this platform with the aim to reach researchers worldwide and establish close successful partnerships with them. Together, we will bring major breakthroughs in the field of medical dermatology and add real value to patients living with severe skin conditions" said **Dr. Bhushan Hardas, Executive Vice President R&D, Chief Scientific Officer of Almirall.**

AlmirallShare was launched in 2017 as an R&D platform designed to interact with different reference centres in dermatology and advance breakthrough research in this field, offering funding and scientific support to the selected proposals. *"We are very excited about the response that this innovation platform has had among the scientific community around the world. AlmirallShare has become an important tool to implement strategic collaborations in Almirall R&D,"* has concluded **Maribel Crespo, AlmirallShare's leader.**

Four new collaboration projects in 2019

- The collaborative project lead by Dr. M. Freeley and Dr. P. Leonard from the **School of Biotechnology of Dublin City University** aims to identify novel therapeutic targets on skin-homing T-cells that could be of use for the identification of new treatments for inflammatory skin disorders, such as psoriasis and atopic dermatitis.
- **The Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)**, through his Principal Investigator Prof. F. Lozano from the immune receptors of the innate and adaptative system group, will work in cooperation with Almirall to analyse the immunomodulatory properties of soluble human CD6 (shCD6) in experimental models of inflammatory skin diseases.

- The partnership with **EvoBiotech, a spin-off of the University of Turin** lead by Prof. Dr. G. Camussi will assess the use of therapeutic activity of extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs) on atopic dermatitis.
- Researchers led by Prof. Y. Poumay from the **Namur Research Institute for Life Sciences (Narilis)** at the University of Namur (Belgium) are exploring the involvement of novel receptors and signaling pathways in the phenotypic alterations of keratinocytes in atopic dermatitis, investigating their potential relevance for this disease and treatments.

AlmirallShare. Bringing Science and creativity together

AlmirallShare was launched in 2017 as an open innovation R&D platform designed to facilitate the establishment of collaborations in dermatological research and find innovative solutions in medical dermatology. By putting together the science and creativity of experts around the world and Almirall's own expertise, the AlmirallShare initiative accelerates the generation of new treatments for skin conditions. The main objectives of this project are to open up the innovation process to foster collaboration projects with partners worldwide, to share opportunities and knowledge with the scientific community in a structured, agile, and transparent manner, as well as to identify innovative solutions to dermatological needs and challenges. AlmirallShare aims to reach out to scientists at universities, public or private research institutions, hospitals, start-ups, and biotechnology and pharmaceutical companies to address challenges such as the identification of therapeutic targets and experimental disease models, the development of new therapeutic treatments as well as novel technologies in dermatology. Almirall converts these challenges into Calls for Proposals (CFPs) that are then published in sharedinnovation.almirall.com

About Almirall

Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying Science to provide medical solutions to patients and future generations. Our efforts are focused on fighting against skin health diseases and helping people feel and look their best. We support healthcare professionals by continuous improvement, bringing our innovative solutions where they are needed.

The company, founded 75 years ago with headquarters in Barcelona, is listed on the Spanish Stock Exchange (ticker: ALM). Almirall has been key in value creation to society according to its commitment with to major shareholders and through its decision to help others, to understand their challenges and to use Science to provide solutions for real life. Total revenues in 2018 were 811 million euros. More than 1,800 employees are devoted to Science.

For more information, please visit almirall.com

Media contact

LLYC

Carmen de la Llave
cdeallave@llorenteycuenca.com

Phone.: (+34) 93 217 22 17

Almirall

Corporate Communications contact:
 Noel Ortiz
noel.ortiz@almirall.com
 Phone.: (+34) 932 913 000

Investors Relations contact:
 Pablo Divasson del Fraile
pablo.divasson@almirall.com
 Phone: (+34) 932 913 087

Legal warning

This document includes only summary information and is not intended to be exhaustive. The facts, figures and opinions contained in this document, in addition to the historical ones, are "forward-looking statements". These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable. These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The Company expressly waives any obligation to revise or update any forward-looking statements, goals or estimates contained in this document to reflect any changes in the assumptions, events or circumstances on which such forward-looking statements are based, unless required by the applicable law.

If you wish to unsubscribe from any Almirall Corporate Communication [click here](#)

In accordance with the General Data Protection Regulation and the applicable local regulations, we inform you that your personal data is processed by Almirall S.A. with registered address at Ronda del General Mitre 151, -08022-, Barcelona (Spain), acting as Controller in line with the purposes indicated in our Privacy Policy. For further information, you may consult it at <https://www.almirall.com/privacy-policy> or contact our Data Protection Officer at the e-mail address: dpo.global@almirall.com. PRNewswire is the Agency that licenses your personal data according to their privacy policy <https://gdpr.cision.com/gdpr>. At any time you can exercise your rights of access, rectification, deletion, objection, portability as well as the limitation of the processing of your data in the terms provided in the current regulations on Data Protection, by addressing the corresponding written request to our postal address (Ronda General Mitre, 151, 08022 Barcelona, Spain). The request to exercise any of your rights must be accompanied by a copy of an official document that identifies you (ID, driver's license or passport). Finally, we inform you that you can contact the Spanish Data Protection Agency and any other competent public bodies for any claim arising from the processing of your personal data.